ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to ...

ADCT has been the subject of several other reports. Stephens increased their price target on ADC Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on ...

1 Day ADCT -4.07% DJIA -5.50% Russell 2K -4.37% Health Care/Life Sciences 4.56% ...